Singer M, Deutschman CS, Seymour CW, et al. The third international consensus definitions for sepsis and septic shock (sepsis-3). JAMA. 2016;315(8):801–10. https://doi.org/10.1001/jama.2016.0287.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Fleischmann-Struzek C, Goldfarb DM, Schlattmann P, Schlapbach LJ, Reinhart K, Kissoon N. The global burden of paediatric and neonatal sepsis: a systematic review. Lancet Respir Med. 2018;6(3):223–30. https://doi.org/10.1016/S2213-2600(18)30063-8.

Article  PubMed  Google Scholar 

Balamuth F, Weiss SL, Neuman MI, et al. Pediatric severe sepsis in US children’s hospitals. Pediatr Crit Care Med J Soc Crit Care Med World Fed Pediatr Intensive Crit Care Soc. 2014;15(9):798–805. https://doi.org/10.1097/PCC.0000000000000225.

Article  Google Scholar 

Odetola FO, Gebremariam A, Freed GL. Patient and hospital correlates of clinical outcomes and resource utilization in severe pediatric sepsis. Pediatrics. 2007;119(3):487–94. https://doi.org/10.1542/peds.2006-2353.

Article  PubMed  Google Scholar 

Ruth A, McCracken CE, Fortenberry JD, Hall M, Simon HK, Hebbar KB. Pediatric severe sepsis: current trends and outcomes from the pediatric health information systems database. Pediatr Crit Care Med J Soc Crit Care Med World Fed Pediatr Intensive Crit Care Soc. 2014;15(9):828–38. https://doi.org/10.1097/PCC.0000000000000254.

Article  Google Scholar 

Watson RS, Crow SS, Hartman ME, Lacroix J, Odetola FO. Epidemiology and outcomes of pediatric multiple organ dysfunction syndrome. Pediatr Crit Care Med J Soc Crit Care Med World Fed Pediatr Intensive Crit Care Soc. 2017;18(3):S4–16. https://doi.org/10.1097/PCC.0000000000001047.

Article  Google Scholar 

Weiss SL, Peters MJ, Alhazzani W, et al. Surviving sepsis campaign international guidelines for the management of septic shock and sepsis-associated organ dysfunction in children. Pediatr Crit Care Med J Soc Crit Care Med World Fed Pediatr Intensive Crit Care Soc. 2020;21(2):e52–106. https://doi.org/10.1097/PCC.0000000000002198.

Article  Google Scholar 

Leteurtre S, Martinot A, Duhamel A, et al. Validation of the paediatric logistic organ dysfunction (PELOD) score: prospective, observational, multicentre study. Lancet Lond Engl. 2003;362(9379):192–7. https://doi.org/10.1016/S0140-6736(03)13908-6.

Article  Google Scholar 

Shakoory B, Carcillo JA, Chatham WW, et al. Interleukin-1 receptor blockade is associated with reduced mortality in sepsis patients with features of macrophage activation syndrome: reanalysis of a prior phase III trial. Crit Care Med. 2016;44(2):275–81. https://doi.org/10.1097/CCM.0000000000001402.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Carcillo JA, Halstead ES, Hall MW, et al. Three hypothetical inflammation pathobiology phenotypes and pediatric sepsis-induced multiple organ failure outcome. Pediatr Crit Care Med J Soc Crit Care Med World Fed Pediatr Intensive Crit Care Soc. 2017;18(6):513–23. https://doi.org/10.1097/PCC.0000000000001122.

Article  Google Scholar 

Seymour CW, Kennedy JN, Wang S, et al. Derivation, validation, and potential treatment implications of novel clinical phenotypes for sepsis. JAMA. 2019;321(20):2003–17. https://doi.org/10.1001/jama.2019.5791.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Leventogiannis K, Kyriazopoulou E, Antonakos N, et al. Toward personalized immunotherapy in sepsis: the PROVIDE randomized clinical trial. Cell Rep Med. 2022;3(11): 100817. https://doi.org/10.1016/j.xcrm.2022.100817.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Dean JM. Evolution of the collaborative pediatric critical care research network (CPCCRN). Pediatr Crit Care Med J Soc Crit Care Med World Fed Pediatr Intensive Crit Care Soc. 2022;23(12):1049–55. https://doi.org/10.1097/PCC.0000000000003098.

Article  Google Scholar 

Tandukar S, Palevsky PM. Continuous renal replacement therapy: who, when, why, and how. Chest. 2019;155(3):626–38. https://doi.org/10.1016/j.chest.2018.09.004.

Article  CAS  PubMed  Google Scholar 

Ricci Z, Goldstein SL. Pediatric continuous renal replacement therapy. Contrib Nephrol. 2016;187:121–30. https://doi.org/10.1159/000442370.

Article  PubMed  Google Scholar 

Cohen S, Hurd E, Cush J, et al. Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2002;46(3):614–24. https://doi.org/10.1002/art.10141.

Article  CAS  PubMed  Google Scholar 

Goldbach-Mansky R, Dailey NJ, Canna SW, et al. Neonatal-onset multisystem inflammatory disease responsive to interleukin-1beta inhibition. N Engl J Med. 2006;355(6):581–92. https://doi.org/10.1056/NEJMoa055137.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Carter SJ, Tattersall RS, Ramanan AV. Macrophage activation syndrome in adults: recent advances in pathophysiology, diagnosis and treatment. Rheumatol Oxf Engl. 2019;58(1):5–17. https://doi.org/10.1093/rheumatology/key006.

Article  CAS  Google Scholar 

Kumar B, Aleem S, Saleh H, Petts J, Ballas ZK. A personalized diagnostic and treatment approach for macrophage activation syndrome and secondary hemophagocytic lymphohistiocytosis in adults. J Clin Immunol. 2017;37(7):638–43. https://doi.org/10.1007/s10875-017-0439-x.

Article  PubMed  Google Scholar 

Rajasekaran S, Kruse K, Kovey K, et al. Therapeutic role of anakinra, an interleukin-1 receptor antagonist, in the management of secondary hemophagocytic lymphohistiocytosis/sepsis/multiple organ dysfunction/macrophage activating syndrome in critically ill children*. Pediatr Crit Care Med J Soc Crit Care Med World Fed Pediatr Intensive Crit Care Soc. 2014;15(5):401–8. https://doi.org/10.1097/PCC.0000000000000078.

Article  Google Scholar 

Fisher CJ, Slotman GJ, Opal SM, et al. Initial evaluation of human recombinant interleukin-1 receptor antagonist in the treatment of sepsis syndrome: a randomized, open-label, placebo-controlled multicenter trial. Crit Care Med. 1994;22(1):12–21. https://doi.org/10.1097/00003246-199401000-00008.

Article  PubMed  Google Scholar 

Fisher CJ, Dhainaut JF, Opal SM, et al. Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial. Phase III rhIL-1ra sepsis syndrome study group. JAMA. 1994;271(23):1836–43.

Article  PubMed  Google Scholar 

Opal SM, Fisher CJ, Dhainaut JF, et al. Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. The interleukin-1 receptor antagonist sepsis investigator group. Crit Care Med. 1997;25(7):1115–24. https://doi.org/10.1097/00003246-199707000-00010.

Article  CAS  PubMed  Google Scholar 

Watt KM, Cohen-Wolkowiez M, Barrett JS, et al. Physiologically based pharmacokinetic approach to determine dosing on extracorporeal life support: fluconazole in children on ECMO. CPT Pharmacomet Syst Pharmacol. 2018;7(10):629–37. https://doi.org/10.1002/psp4.12338.

Article  CAS  Google Scholar 

Fuhr LM, Hanke N, Meibohm B, Lehr T. Effective removal of dabigatran by idarucizumab or hemodialysis: a physiologically based pharmacokinetic modeling analysis. Clin Pharmacokinet. 2020;59(6):809–25. https://doi.org/10.1007/s40262-019-00857-y.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Dubinsky SDJ, Watt KM, Imburgia CE, et al. Anakinra removal by continuous renal replacement therapy: an ex vivo analysis. Crit Care Explor. 2023;5(12): e1010. https://doi.org/10.1097/CCE.0000000000001010.

Article  PubMed  PubMed Central  Google Scholar 

Niederalt C, Kuepfer L, Solodenko J, et al. A generic whole body physiologically based pharmacokinetic model for therapeutic proteins in PK-Sim. J Pharmacokinet Pharmacodyn. 2018;45(2):235–57. https://doi.org/10.1007/s10928-017-9559-4.

Article  CAS  PubMed  Google Scholar 

Willmann S, Höhn K, Edginton A, et al. Development of a physiology-based whole-body population model for assessing the influence of individual variability on the pharmacokinetics of drugs. J Pharmacokinet Pharmacodyn. 2007;34(3):401–31. https://doi.org/10.1007/s10928-007-9053-5.

Article  PubMed  Google Scholar 

Schlender JF, Meyer M, Thelen K, et al. Development of a whole-body physiologically based pharmacokinetic approach to assess the pharmacokinetics of drugs in elderly individuals. Clin Pharmacokinet. 2016;55(12):1573–89. https://doi.org/10.1007/s40262-016-0422-3.

Article  CAS